Altimmune (ALT) Total Liabilities (2010 - 2026)

Altimmune (ALT) has 17 years of Total Liabilities data on file, last reported at $51.6 million in Q1 2026.

• On a quarterly basis, Total Liabilities rose 241.98% year-over-year to $51.6 million in Q1 2026; TTM through Mar 2026 was $51.6 million, a 241.98% increase from a year earlier, with the FY2025 full-year figure at $55.0 million, up 248.38% from the prior year.
• Total Liabilities for Q1 2026 stood at $51.6 million, down from $55.0 million in the prior quarter.
• Over the last five years, Total Liabilities for ALT reached as high as $55.0 million in Q4 2025 and fell as low as $14.5 million in Q3 2024.
• Historically, Total Liabilities has averaged $23.3 million across 5 years, with a median of $19.4 million in 2023.
• Across the five-year window, Total Liabilities slipped 26.75% in 2022 and jumped 248.38% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $21.6 million in 2022, then retreated by 23.55% to $16.5 million in 2023, then slipped by 4.49% to $15.8 million in 2024, then soared by 248.38% to $55.0 million in 2025, then dropped by 6.17% to $51.6 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $51.6 million in Q1 2026, $55.0 million in Q4 2025, and $32.8 million in Q3 2025.